Latest Articles
Aprea reports second partial response in endometrial cancer trial By Investing.com - Investing.com South Africa
Aprea reports second partial response in endometrial cancer trial By Investing.com Investing.com South Africa
Published: Feb. 19, 2026, 12:54 a.m.
Aprea reports second partial response in endometrial cancer trial - Investing.com Nigeria
Aprea reports second partial response in endometrial cancer trial Investing.com Nigeria
Published: Feb. 18, 2026, 11:46 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider
Published: Feb. 18, 2026, 3:28 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider
Published: Feb. 18, 2026, 3:28 p.m.
Aprea reports second partial response in endometrial cancer trial - Investing.com
Aprea reports second partial response in endometrial cancer trial Investing.com
Published: Feb. 18, 2026, 1:42 p.m.
GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk - European Medical Journal
GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk European Medical Journal
Published: Feb. 18, 2026, noon
GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk - EMJ | Elevating the quality of healthcare globally
GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk EMJ | Elevating the quality of healthcare globally
Published: Feb. 18, 2026, noon
A 60-Year-Old Woman With Endometrial Intraepithelial Neoplasia: A Case of Persistent Postmenopausal Bleeding - Cureus
A 60-Year-Old Woman With Endometrial Intraepithelial Neoplasia: A Case of Persistent Postmenopausal Bleeding Cureus
Published: Feb. 18, 2026, 2:58 a.m.
Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... - Medical Dialogues
Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... Medical Dialogues
Published: Feb. 17, 2026, 3:15 p.m.
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia - 2 Minute Medicine
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia 2 Minute Medicine
Published: Feb. 17, 2026, 12:15 a.m.
Link copied to clipboard!